4.0 Article

Amplification of the response to toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: Implication for the pathogenesis of macrophage activation syndrome

期刊

ARTHRITIS AND RHEUMATISM
卷 64, 期 5, 页码 1680-1688

出版社

WILEY-BLACKWELL
DOI: 10.1002/art.33496

关键词

-

资金

  1. IRCCS
  2. F. Hoffmann-La Roche
  3. Pfizer
  4. Abbott
  5. Bristol-Myers Squibb
  6. MedImmune

向作者/读者索取更多资源

Objective To investigate whether prolonged exposure to interleukin-6 (IL-6) affects the inflammatory response induced by Toll-like receptor (TLR) ligands. Methods IL-6transgenic mice and wild-type mice were stimulated with different TLR ligands; survival rates, blood cell counts, and biochemical parameters were analyzed. Murine splenic mononuclear cells and peritoneal macrophages were stimulated with lipopolysaccharide (LPS), lipoteichoic acid, poly(I-C), or CpG. Human macrophages were cultured for 4 days in the presence of IL-6 and then stimulated with LPS. Inflammatory cytokine expression was measured by enzyme-linked immunosorbent assay or reverse transcriptionpolymerase chain reaction. Activation of STAT-3, ERK-1/2 (MAPK), and p65 NF-?B was evaluated by Western blotting or confocal analysis. Results Treatment of IL-6transgenic mice with TLR ligands led to an increased fatality rate and elevated levels of IL-1 beta, tumor necrosis factor a (TNFa), IL-6, and IL-18. Macrophages from IL-6transgenic mice produced increased levels of inflammatory cytokines, which were associated with increased phosphorylation of STAT-3 and ERK-1/2 and with increased NF-?B nuclear translocation. Human macrophages treated with IL-6 and then stimulated with LPS showed elevated levels of cytokines and similarly elevated signaling pathway activation. After LPS administration, IL-6transgenic mice showed an increase in ferritin and soluble CD25 levels, as well as a decrease in platelet and neutrophil counts and in hemoglobin levels compared to wild-type mice. Conclusion Our findings indicate that prolonged exposure to IL-6 in vivo and in vitro leads to an exaggerated inflammatory response to TLR ligands. Hematologic and biochemical abnormalities in IL-6transgenic mice treated with LPS show striking similarities to macrophage activation syndrome.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Pediatrics

Update on the treatment of steroid-sensitive nephrotic syndrome

Federica Zotta, Marina Vivarelli, Francesco Emma

Summary: Steroid-sensitive nephrotic syndrome (SSNS) is rare and mainly affects preadolescent children, with corticosteroids being the mainstay of treatment. Many patients require second-line therapy to reduce drug side effects and maintain remission as long as possible.

PEDIATRIC NEPHROLOGY (2022)

Article Biochemistry & Molecular Biology

Preparation and In Vitro Evaluation of RITUXfab-Decorated Lipoplexes to Improve Delivery of siRNA Targeting C1858T PTPN22 Variant in B Lymphocytes

Andrea Arena, Eugenia Belcastro, Antonella Accardo, Annamaria Sandomenico, Olivia Pagliarosi, Elisabetta Rosa, Stefania Petrini, Libenzio Adrian Conti, Ezio Giorda, Tiziana Corsetti, Riccardo Schiaffini, Giancarlo Morelli, Alessandra Fierabracci

Summary: Autoimmune endocrine disorders such as type 1 diabetes and thyroiditis currently rely on hormone replacement therapy, highlighting the need for personalized immunotherapeutic strategies targeting T and B lymphocytes. This study improved upon a personalized immunotherapeutic approach by functionalizing liposomes with Rituximab antibody, specifically targeting B lymphocytes in conditions like type 1 diabetes. The results showed that these functionalized liposomes had a significant inhibitory effect on the function of B lymphocytes, suggesting potential applicability for personalized immunotherapy in other autoimmune disorders where B lymphocytes are the primary pathogenic immune cells.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Biochemistry & Molecular Biology

CAPE and its synthetic derivative VP961 restore BACH1/NRF2 axis in Down Syndrome

Sara Pagnotta, Antonella Tramutola, Eugenio Barone, Fabio Di Domenico, Valeria Pittala, Loredana Salerno, Valentina Folgiero, Matteo Caforio, Franco Locatelli, Stefania Petrini, D. Allan Butterfield, Marzia Perluigi

Summary: This study focuses on the role of BACH1/NRF2 ratio in the regulation of antioxidant response and its impact on patients with Down syndrome. The results show that overexpression of BACH1 disrupts the induction of antioxidant response genes, leading to oxidative damage accumulation. Additionally, administration of CAPE and VP961 promotes NRF2 nuclear translocation in cells from Down syndrome patients, improving antioxidant response.

FREE RADICAL BIOLOGY AND MEDICINE (2022)

Letter Urology & Nephrology

Clinical Factors and Adverse Kidney Outcomes in Children With Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis

Matko Marlais, Tanja Wlodkowski, Nikoleta Printza, Dorothea Kronsteiner, Regina Krisam, Lukas Sauer, Marina Aksenova, Isa Ashoor, Atif Awan, Justine Bacchetta, Ramnath Balasubramanian, Biswanath Basu, Zivile Bekassy, Olivia Boyer, Eugene Yu-hin Chan, Dagmar Csaicsich, Stephane Decramer, Eiske Dorresteijn, Magdalena Drozynska-Duklas, Loai Akram Eid, Laura Espinosa, Veronica Ferraris, Hana Flogelova, Jessica Forero-Delgadillo, Alessandra Gianviti, Valentina Gracchi, Mercedes Lopez Gonzalez, Matthias Hansen, Motoshi Hattori, Xu Hong, Nakysa Hooman, Dmytro Ivanov, Hee Gyung Kang, Vasiliki Karava, Ina Kazyra, Adrian Lungu, Stephen Marks, Andrew Maxted, Anna Moczulska, Rebekka Mueller, Tatiana Nastausheva, Mattia Parolin, Carmine Pecoraro, Iliana Principi, Cheryl Sanchez-Kazi, Seha Saygili, Raphael Schild, Mohan Shenoy, Rajiv Sinha, Ana Paula Spizzirri, Maria Stack, Maria Szczepanska, Alexey Tsygin, Julia Tzeng, Vaidotas Urbonas, Carlos Zapata, Jakub Zieg, Franz Schaefer, Marina Vivarelli, Kjell Tullus

AMERICAN JOURNAL OF KIDNEY DISEASES (2023)

Article Pediatrics

IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome

Agnes Trautmann, Olivia Boyer, Elisabeth Hodson, Arvind Bagga, Debbie S. Gipson, Susan Samuel, Jack Wetzels, Khalid Alhasan, Sushmita Banerjee, Rajendra Bhimma, Melvin Bonilla-Felix, Francisco Cano, Martin Christian, Deirdre Hahn, Hee Gyung Kang, Koichi Nakanishi, Hesham Safouh, Howard Trachtman, Hong Xu, Wendy Cook, Marina Vivarelli, Dieter Haffner

Summary: Idiopathic nephrotic syndrome is a common pediatric glomerular disease, and patients who are sensitive to steroids have a risk of relapse and may require long-term medication to maintain remission. The optimal dose and duration of steroid treatment to prolong time between relapses are still debated, and there is variation in practice regarding drug selection and timing. Therefore, international evidence-based clinical practice recommendations are needed to guide treatment and reduce practice variation.

PEDIATRIC NEPHROLOGY (2023)

Editorial Material Transplantation

Steroid-sensitive nephrotic syndrome in children

Olivia Boyer, Agnes Trautmann, Dieter Haffner, Marina Vivarelli

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Article Pediatrics

Treatment of idiopathic nephrotic syndrome at onset: a comparison between 8-and 12-week regimens in everyday clinical practice

Laura Lucchetti, Antonio Gatto, Alessandra Gianviti, Marina Vivarelli, Francesco Emma, Laura Massella

Summary: The aim of this study was to compare the clinical outcomes of two different steroid regimens in patients with steroid-sensitive nephrotic syndrome over a 24-month follow-up period. The results showed that there was no difference in cumulative prednisone dosage between the two regimens at 12 and 24 months, but patients treated with the 8-week regimen had a lower relapse rate at 6 and 12 months.

PEDIATRIC NEPHROLOGY (2023)

Review Biochemistry & Molecular Biology

Novel Aspects of the Immune Response Involved in the Peritoneal Damage in Chronic Kidney Disease Patients under Dialysis

Flavia Trionfetti, Vanessa Marchant, Guadalupe. T. T. Gonzalez-Mateo, Edyta Kawka, Laura Marquez-Exposito, Alberto Ortiz, Manuel Lopez-Cabrera, Marta Ruiz-Ortega, Raffaele Strippoli

Summary: The global incidence of chronic kidney disease (CKD) is increasing, leading to a significant number of CKD patients developing end-stage renal disease (ESRD) and requiring kidney replacement therapies (KRT). Peritoneal dialysis (PD) is a convenient home therapy for KRT, but it can lead to damage of the peritoneal membrane (PM) due to the exposure to PD fluids containing high concentrations of glucose or other osmotic agents. This damage involves inflammation and fibrosis, which can be worsened by peritonitis episodes. In this article, we review the role of immune cells in PM damage during KRT and infections, as well as the anti-inflammatory properties of current clinical treatments for CKD patients in KRT and their potential effect on preserving PM integrity. Additionally, we discuss the implications of COVID-19 in CKD and KRT.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Review Urology & Nephrology

Renal involvement in monogenic autoinflammatory diseases: A narrative review

Saverio La Bella, Armando Di Ludovico, Giulia Di Donato, Giovanna Scorrano, Francesco Chiarelli, Marina Vivarelli, Luciana Breda

Summary: Autoinflammatory diseases (AIDs) are primarily caused by dysfunctions in single genes encoding for proteins involved in innate immunity regulation. Renal health is frequently affected by unprovoked inflammation due to the deposition of amyloid A (AA) fibrils in the glomeruli. AA amyloidosis, caused by elevated levels of serum amyloid A (SAA) and a genetic predisposition, is the most common form of amyloidosis in children. This review focuses on describing the renal implications in pediatric patients with inflammasomopathies, type-I interferonopathies, and other rare AIDs, aiming to improve their clinical course and quality of life.

NEPHROLOGY (2023)

Article Pediatrics

Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN survey

Aleksandra Zurowska, Magdalena Drozynska-Duklas, Rezan Topaloglu, Antonia Bouts, Olivia Boyer, Mohan Shenoy, Marina Vivarelli

Summary: There is limited information on the association between rituximab and hypogammaglobulinemia (HGG) in children with idiopathic nephrotic syndrome (INS). A survey showed that most pediatric nephrology units have different practices in recognizing and managing RTX-associated HGG and its morbidity and mortality. HGG was observed in 80% of children with severe infections, highlighting the need for mandatory screening for HGG in children treated with RTX.

PEDIATRIC NEPHROLOGY (2023)

Article Pediatrics

A pediatric case of IgA nephropathy benefitting from targeted release formulation-budesonide

Luca Antonucci, Manuela Colucci, Francesco Emma, Marina Vivarelli

Summary: This case demonstrates that TRF-budesonide could be considered an effective second-line treatment in pediatric IgAN, especially when a long course of steroids is necessary to control active inflammation. However, pediatric clinical trials are urgently needed to identify the correct dosage and tolerability of TRF-budesonide.

PEDIATRIC NEPHROLOGY (2023)

Review Pediatrics

Complement inhibitors in pediatric kidney diseases: new therapeutic opportunities

Luca Antonucci, Joshua M. Thurman, Marina Vivarelli

Summary: The complement system plays a crucial role in kidney diseases, and complement inhibitors have shown potential in improving their outcomes. This article provides a summary of the main complement inhibitors used in nephrology and discusses their efficacy in different complement-mediated kidney diseases. These novel drugs have the potential to significantly improve the prognosis of kidney diseases.

PEDIATRIC NEPHROLOGY (2023)

Article Rheumatology

Long-Term Efficacy and Safety of Canakinumab in Patients With Tumor Necrosis Factor Receptor-Associated Periodic Syndrome: Results From a Phase III Trial

Marco Gattorno, Laura Obici, Inmaculada Calvo Penades, Tilmann Kallinich, Susanne Benseler, Elise Dekker, Jeremy Levy, Fabrizio De Benedetti, Helen Lachmann

Summary: This study assessed the efficacy, safety, and tolerability of canakinumab in TRAPS patients during a 72-week long-term, open-label extension. The results showed that long-term canakinumab treatment effectively controlled disease activity and reduced flare incidence in TRAPS patients. No new safety concerns were identified.

ARTHRITIS & RHEUMATOLOGY (2023)

Article Rheumatology

Efficacy and safety of emapalumab in macrophage activation syndrome

Fabrizio De Benedetti, Alexei A. Grom, Paul A. Brogan, Claudia Bracaglia, Manuela Pardeo, Giulia Marucci, Despina Eleftheriou, Charalampia Papadopoulou, Grant S. Schulert, Pierre Quartier, Jordi Anton, Christian Laveille, Rikke Frederiksen, Veronica Asnaghi, Maria Ballabio, Philippe Jacqmin, Cristina de Min

Summary: The objective of this study was to confirm the adequacy of an emapalumab dosing regimen in relation to interferon-γ (IFN-γ) activity and assess its efficacy and safety in treating MAS secondary to sJIA or AOSD. The results showed that emapalumab was efficacious in inducing remission of MAS and viral infections were observed.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Meeting Abstract Biochemistry & Molecular Biology

In acute hemolytic uremic syndrome induced by Shiga-like toxin producing E.coli (STEC-HUS) activation of the complement alternative pathway favors thrombus formation on microvascular endothelial cells

Donata Santarsiero, Miriam Galbusera, Sara Gastoldi, Anna Schubart, Marina Vivarelli, Elena Bresin, Ariela Benigni, Marina Noris, Giuseppe Remuzzi

MOLECULAR IMMUNOLOGY (2022)

暂无数据